Cantor Fitzgerald Adjusts AbbVie Price Target to $265 From $240
AbbVie (ABBV) has an average rating of overweight and mean price target of $258.12, according to analysts polled by FactSet. ( covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: )
Story updates
12:49:28 PM UTC
SquawkNews
Cantor Fitzgerald analyst Carter Gould maintains AbbVie (NYSE: ABBV ) with a Overweight and raises the price target from $240 to $265.
AbbVie (ABBV) has an average rating of overweight and mean price target of $258.12, according to analysts polled by FactSet. ( covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe.
Research providers may contact us here: )